Oxypurinol (Oxipurinol)

10/31/1986 - "Monitoring of plasma oxipurinol levels (ideally less than 100 mumol/l) by high-pressure liquid chromatography is helpful for adjusting dosage in renal failure. "
12/01/2015 - "Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin."
12/01/1996 - "In renal insufficiency, the drug must be used cautiously and in reduced dosage because increased serum concentration of oxipurinol, active metabolite of allopurinol, may induce severe side effect."
12/01/1996 - "In some of the patients with renal insufficiency (CCr < 30 ml/min), daily administration of 100 mg of allopurinol resulted in a serum concentration of oxipurinol over 15.2 micrograms/ml. 3. For patients with renal insufficiency (CCr < 30 ml/min), administration of allopurinol at the dosage of 50 mg/day is considered adequate to avoid the accumulation of serum oxipurinol."
10/01/1986 - "Allopurinol toxicity has been associated with the use of this drug in patients with renal insufficiency, a situation where the half-life of oxipurinol, the major metabolite of allopurinol, is prolonged. "

10/25/2009 - "These results indicate that the beneficial effects of antioxidation can be sustained by long-term treatment with oxypurinol after ischemic heart failure, with significantly improved cardiac contractility."
06/17/2008 - "(Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687)."
06/17/2008 - "Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. "
06/17/2008 - "Impact of oxypurinol in patients with symptomatic heart failure. "
01/01/2004 - "In July 2003, the US Patent and Trademark Office issued a new patent providing additional protection to Cardiome's programme focused on treatment of congestive heart failure with oxypurinol. "

09/01/2010 - "The aim of this study was to develop an HPLC-tandem mass spectrometry method to measure oxypurinol in urine to facilitate the study of the renal elimination of oxypurinol in patients with gout. "
01/01/2004 - "Cardiome stated in May 2002 that it intended to commence a further phase II trial of oxypurinol in gout. "
07/01/2023 - "A tool to identify people with gout who require additional support to maintain adherence using plasma oxypurinol concentrations was developed and evaluated. "
01/01/2017 - "Oxypurinol plasma concentrations from 6 gout people receiving haemodialysis and 19 people with gout not receiving dialysis were used to develop a population pharmacokinetic model in NONMEM. "
09/01/2012 - "The pharmacokinetics of oxypurinol in people with gout."

01/01/1993 - "In animals given oxypurinol at 5 mg/kg BW 40 min after ischemia, the CIn was significantly greater than in those receiving buffered saline. "
05/01/1995 - "Oxypurinol administration resulted in a significant increase in the energy charge both during ischemia and after 5 min of reperfusion. "
12/01/1989 - "Oxypurinol attenuates ischemia-induced hippocampal damage in the gerbil."
01/01/1988 - "We conclude that oxypurinol administered following 30 min of total ischemia at the onset of reperfusion, can preserve myocardial function during the early reperfusion period in the isolated rat heart."
01/01/1988 - "Each heart was then subjected to 30 min of total ischemia at 37 degrees C followed by 40 min of reperfusion with either saline-treated perfusate or oxypurinol-treated perfusate (1.3 mM). "

02/01/1994 - "These studies suggest that cell-mediated immunity directed toward allopurinol and more importantly to its oxypurinol metabolite is involved in the pathogenesis of allopurinol-induced hypersensitivity."
11/01/2023 - "The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug-reactive T cells in resolved hypersensitivity cases and drug-naïve healthy donors."
11/01/2013 - "Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response."
04/01/2009 - "Severe allopurinol hypersensitivity reactions are not necessarily dose-dependent and do not always correlate with serum oxypurinol levels. "
04/01/2009 - "This situation has been promoted by longstanding, non-evidence-based guidelines for allopurinol use calibrated to renal function (and oxypurinol levels) and designed, without proof of efficacy, to avoid allopurinol hypersensitivity syndrome. "